{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:04:55Z","timestamp":1790798695697,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["CI-99-18"],"award-info":[{"award-number":["CI-99-18"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA082103"],"award-info":[{"award-number":["P30CA082103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-GM-136547"],"award-info":[{"award-number":["T32-GM-136547"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019364","name":"Revolution Medicines","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.xcrm.2023.101290","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T05:10:02Z","timestamp":1701321002000},"page":"101290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7960-5218","authenticated-orcid":false,"given":"Bogdan","family":"Popescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Stahlhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Tarver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Wishner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.C.","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuyler","family":"Luck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Phojanakong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Camara Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simayijiang","family":"Xirenayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Chukinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0160-7026","authenticated-orcid":false,"given":"Catherine C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101290_bib1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib4","first-page":"190","article-title":"FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group","volume":"111","author":"Abu-Duhier","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2023.101290_bib5","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101290_bib6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","article-title":"KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival","volume":"107","author":"Schnittger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2023.101290_bib8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2023.101290_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib10","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2023.101290_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2023.101290_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101290_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101290_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/bloodadvances.2020003398","article-title":"Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib","volume":"5","author":"Peretz","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2023.101290_bib17","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101290_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101290_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib21","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1200\/JCO.2013.48.7488","article-title":"KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase\/AKT Dysregulation","volume":"33","author":"Serrano","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101290_bib22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.xcrm.2023.101290_bib23","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/MCB.23.21.7875-7886.2003","article-title":"Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling","volume":"23","author":"Agazie","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2023.101290_bib24","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1074\/jbc.M312498200","article-title":"Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty","volume":"279","author":"Hanafusa","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jcp.10446","article-title":"SHP-2 regulates the phosphatidylinositide 3\u2019-kinase\/Akt pathway and suppresses caspase 3-mediated apoptosis","volume":"199","author":"Ivins Zito","year":"2004","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.xcrm.2023.101290_bib26","doi-asserted-by":"crossref","first-page":"52021","DOI":"10.1074\/jbc.M306758200","article-title":"SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination\/degradation downstream of the prolactin receptor","volume":"278","author":"Ali","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib27","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2010-06-288910","article-title":"A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/leu.2012.308","article-title":"The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in\u00a0vivo","volume":"27","author":"Nabinger","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2023.101290_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2023.101290_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in\u00a0vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib31","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1172\/JCI130520","article-title":"SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations","volume":"129","author":"Pandey","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.101290_bib32","doi-asserted-by":"crossref","first-page":"e20201414","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib33","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101290_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.xcrm.2023.101290_bib35","doi-asserted-by":"crossref","first-page":"100538","DOI":"10.1016\/j.jbc.2021.100538","article-title":"A novel partially open state of SHP2 points to a \u201cmultiple gear\u201d regulation mechanism","volume":"296","author":"Tao","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib36","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101290_bib37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2023.101290_bib38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2023.101290_bib39","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2023.101290_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2023.101290_bib41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","article-title":"Mechanisms of Interferon-alpha induced apoptosis in malignant cells","volume":"21","author":"Thyrell","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2023.101290_bib42","doi-asserted-by":"crossref","first-page":"24152","DOI":"10.1074\/jbc.M312219200","article-title":"Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase\/mammalian target of rapamycin signaling pathway","volume":"279","author":"Thyrell","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib43","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1074\/jbc.M110.207068","article-title":"The interferon stimulated gene 54 promotes apoptosis","volume":"286","author":"Stawowczyk","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.cdd.4400352","article-title":"The role of 2\u2019-5\u2019 oligoadenylate-activated ribonuclease L in apoptosis","volume":"5","author":"Castelli","year":"1998","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2023.101290_bib45","doi-asserted-by":"crossref","first-page":"25447","DOI":"10.1074\/jbc.M100496200","article-title":"A specific isozyme of 2\u2019-5\u2019 oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family","volume":"276","author":"Ghosh","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ccr.2013.08.011","article-title":"Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7","volume":"24","author":"Nagamachi","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101290_bib47","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1038\/s41467-021-25728-8","article-title":"MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I","volume":"12","author":"Br\u00e4gelmann","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101290_bib48","first-page":"3379","article-title":"Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts","volume":"9","author":"Brunet","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2023.101290_bib49","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3390\/ijms21103460","article-title":"Targeting Actomyosin Contractility Suppresses Malignant Phenotypes of Acute Myeloid Leukemia Cells","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2023.101290_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101290_bib51","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1062257","article-title":"Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis","volume":"293","author":"Puthalakath","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.101290_bib52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0955-0674(00)00251-9","article-title":"Anoikis mechanisms","volume":"13","author":"Frisch","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.xcrm.2023.101290_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2023.101290_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1515\/hsz-2016-0107","article-title":"iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry","volume":"397","author":"Ryan","year":"2016","journal-title":"Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.101290_bib55","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2023.101290_bib56","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib57","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101290_bib58","doi-asserted-by":"crossref","first-page":"e33718","DOI":"10.7554\/eLife.33718","article-title":"Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells","volume":"7","author":"Unni","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2023.101290_bib59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2023.101290_bib60","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2023.101290_bib61","doi-asserted-by":"crossref","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T\u00a0cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2023.101290_bib62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101290_bib63","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/0008-5472.CAN-16-2593","article-title":"Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies","volume":"77","author":"Bruner","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101290_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","article-title":"SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2023.101290_bib65","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101290_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2023.101290_bib67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101290_bib68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2023.101290_bib69","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2023.101290_bib70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2023.101290_bib71","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clml.2018.12.009","article-title":"Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia","volume":"19","author":"Maiti","year":"2019","journal-title":"Clin. Lymphoma, Myeloma\u00a0& Leukemia"},{"key":"10.1016\/j.xcrm.2023.101290_bib72","doi-asserted-by":"crossref","first-page":"106736","DOI":"10.1016\/j.leukres.2021.106736","article-title":"Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial","volume":"111","author":"Luger","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xcrm.2023.101290_bib73","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial","volume":"20","author":"Jain","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101290_bib74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol."},{"key":"10.1016\/j.xcrm.2023.101290_bib75","doi-asserted-by":"crossref","first-page":"e20221563","DOI":"10.1084\/jem.20221563","article-title":"Genome-wide CRISPR\/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition","volume":"220","author":"Wei","year":"2023","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.101290_bib76","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101290_bib77","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2012-07-442871","article-title":"Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD","volume":"121","author":"Smith","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101290_bib78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2023.101290_bib79","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2023.101290_bib80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR Edits from Sanger Trace Data","volume":"5","author":"Conant","year":"2022","journal-title":"CRISPR J."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:58:40Z","timestamp":1770857920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123004846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666379123004846"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101290","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101290"}}